Contents

Search

PREVENT trial

Subgroup analysis [1] 5600 hopsitalized patients at risk for venous thromboembolism 1118 obese patients, 1226 elderly serum creatinine < 2.0 5000 U of dalteparin QD vs placebo Combined endoint: 1) symptomatic venous thromboembolism 2) fatal pulmonary embolism 3) sudden death 4) proximal deep vein thrombosis by ultrasound Results: 1) endpoint reached a) obese: - 2.8% of dalteparin group vs 4.3% in placebo group b) elderly - 4.2% of dalteparin group vs 8.0% in placebo group 2) difference significant only for elderly 3) mortality, hemorrhage, thrombocytopenia not different among groups

Related

dalteparin (Fragmin) venous thromboembolism (VTE)

General

clinical trial

References

  1. Journal Watch 25(7):53, 2005 Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005 Feb 14;165(3):341-5. PMID: 15710801